157 related articles for article (PubMed ID: 37214442)
1. Studies on the inhibitory effect of isavuconazole on flumatinib metabolism
Liu YN; Xu X; Nie J; Hu Y; Xu X; Xu RA; Du X
Front Pharmacol; 2023; 14():1168852. PubMed ID: 37214442
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro.
Shen L; Wang J; Yi Y; Ye C; Wang R; Xia G; Yu C; Tu F; Xu J; Zheng Z
Drug Test Anal; 2019 Apr; 11(4):595-600. PubMed ID: 30370647
[TBL] [Abstract][Full Text] [Related]
3. UPLC-MS/MS Measurement of the Effect of Isavuconazole, Itraconazole and Fluconazole on the Pharmacokinetics of Selinexor in Rats.
Li SL; Zhang Y; Cheng QS; Xin JZ; Dong ZQ; Qiu XJ
Infect Drug Resist; 2020; 13():3153-3161. PubMed ID: 32982330
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC-MS/MS.
Xia M; Song X; Lu Z; Wang Y; Zhou Q; Geng P; Wang S; Zhou Y; Wu Q; Han A
Thorac Cancer; 2023 Nov; 14(33):3331-3341. PubMed ID: 37771131
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous determination of flumatinib and its two major metabolites in plasma of chronic myelogenous leukemia patients by liquid chromatography-tandem mass spectrometry.
Yang Y; Liu K; Zhong D; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():25-30. PubMed ID: 22472641
[TBL] [Abstract][Full Text] [Related]
6. Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism.
Liu YN; Chen J; Wang J; Li Q; Hu GX; Cai JP; Lin G; Xu RA
Arch Toxicol; 2023 Aug; 97(8):2133-2142. PubMed ID: 37209178
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS.
Lin QM; Pang NH; Li YH; Huang HL; Zhang XD; Hu GX; Wang ZS
Chem Biol Interact; 2019 Sep; 310():108744. PubMed ID: 31299239
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of napabucasin on arbidol metabolism and its mechanism research.
Nie J; Xia H; Liu YN; Yu Y; Xu RA
Front Pharmacol; 2023; 14():1292354. PubMed ID: 38094891
[TBL] [Abstract][Full Text] [Related]
9. The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone.
Li Q; Wang J; Wang ZL; Shen Y; Zhou Q; Liu YN; Hu GX; Cai JP; Xu RA
Biomed Pharmacother; 2023 Dec; 168():115833. PubMed ID: 37935069
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients.
Gong A; Chen X; Deng P; Zhong D
Drug Metab Dispos; 2010 Aug; 38(8):1328-40. PubMed ID: 20478851
[TBL] [Abstract][Full Text] [Related]
11. Metabolic interactions between flumatinib and the CYP3A4 inhibitors erythromycin, cyclosporine, and voriconazole.
Chen J; Guo S; Yu X; Lei J; Xu T; Zhu S; Chen L; Xu P; Zhou X; Yu L
Pharmazie; 2020 Sep; 75(9):424-429. PubMed ID: 32797767
[TBL] [Abstract][Full Text] [Related]
12. Development of a UPLC-MS/MS method for the determination of lacosamide and its metabolite and its application to drug-drug interaction.
Chen J; Shen Y; Xia H; Chen X; Xu RA; Lin G; Dai G
Front Pharmacol; 2023; 14():1265252. PubMed ID: 38026954
[TBL] [Abstract][Full Text] [Related]
13. The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism.
Zhou Q; Ye F; Ye Z; Gao N; Kong Q; Hu X; Qian J; Wu B
PeerJ; 2023; 11():e16601. PubMed ID: 38089912
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia.
Jiang B; Qi J; Sun M; Zheng W; Wei Y; Wang J; Zhang F
Front Oncol; 2023; 13():1101738. PubMed ID: 36814813
[TBL] [Abstract][Full Text] [Related]
15. The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism.
Ye Z; Hu J; Wang J; Liu YN; Hu GX; Xu RA
Chem Biol Interact; 2023 Apr; 374():110398. PubMed ID: 36773832
[TBL] [Abstract][Full Text] [Related]
16. Effects of myricetin and quercetin on ticagrelor metabolism and the underlying mechanism.
Wang J; Hu Y; Li Q; Liu YN; Lin J; Xu RA
Chem Biol Interact; 2024 Apr; 392():110924. PubMed ID: 38401715
[TBL] [Abstract][Full Text] [Related]
17.
Tang C; Niu X; Shi L; Zhu H; Lin G; Xu RA
Front Pharmacol; 2020; 11():626897. PubMed ID: 33613287
[TBL] [Abstract][Full Text] [Related]
18. Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats.
Shi Y; Meng D; Wang S; Geng P; Xu T; Zhou Q; Zhou Y; Li W; Chen X
Drug Des Devel Ther; 2021; 15():3661-3673. PubMed ID: 34456561
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of resveratrol on the pharmacokinetic of ibrutinib by UPLC-MS/MS.
Wen J; Bao SS; Zhang BW; Liu TH; Ou-Yang QG; Cai JP; Zhou HY
Drug Dev Ind Pharm; 2019 Jan; 45(1):27-31. PubMed ID: 30156133
[TBL] [Abstract][Full Text] [Related]
20. Effects of bergapten on the pharmacokinetics of macitentan in rats both
Xu J; Zhou Q; Hou P; Wang Y; Geng P; Lu Z; Zhou Y; Dai D; Wang S
Front Pharmacol; 2023; 14():1204649. PubMed ID: 37492094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
